Biodexa Launches Global Early Access Program for eRapa for FAP Patients via Tanner Pharma Partnership
BDRX is trading near its 52-week low of $0.679 (7.4% above the low) on light trading volume (0.2× avg).
Summary
Biodexa Pharmaceuticals has initiated a Global Early Access Program (EAP) for its investigational drug eRapa, targeting Familial Adenomatous Polyposis (FAP) patients. This program, facilitated by a strategic partnership with Tanner Pharma Group, allows clinicians worldwide to prescribe eRapa outside of clinical trials for the first time, addressing an unmet medical need for FAP patients who currently lack approved therapeutic options. The EAP will also generate valuable Real World Data, further expanding the understanding of FAP. This development represents a positive step forward for eRapa, which has Orphan Designation in the US and is supported by a $20 million grant for its planned Phase 3 registrational trial.
At the time of this announcement, BDRX was trading at $0.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $434K. The 52-week trading range was $0.68 to $22.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.